D H Johnson

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi request reprint Targeted therapies in combination with chemotherapy in non-small cell lung cancer
    David H Johnson
    Vanderbilt Ingram Cancer Center and Division of Hematology and Oncology, Vanderbilt University School of Medicine Nashville, Tennessee 37232 6307, USA
    Clin Cancer Res 12:4451s-4457s. 2006
  2. ncbi request reprint Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
    David H Johnson
    Division of Hematology and Oncology, Vanderbilt University Medical School, 777 Preston Research Bldg, Nashville, TN, USA
    J Clin Oncol 22:2184-91. 2004
  3. ncbi request reprint Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: a historical perspective and the eastern cooperative oncology group experience
    D H Johnson
    Division of Medical Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA
    Chest 117:133S-137S. 2000
  4. ncbi request reprint Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer
    B P Nicholson
    Vanderbilt University Cancer Center, Vanderbilt Cancer Center Affiliate Network, Nashville, TN, USA
    Clin Breast Cancer 1:136-43; discussion 144. 2000
  5. ncbi request reprint Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial
    H Choy
    Vanderbilt University Medical School, Nashville, TN, USA
    Lung Cancer 34:441-9. 2001
  6. ncbi request reprint Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial
    D H Johnson
    Department of Medicine, Vanderbilt University Medical School, Nashville, TN, USA
    J Clin Oncol 14:2054-60. 1996
  7. ncbi request reprint Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study
    M H Jagasia
    Vanderbilt University, Nashville, Tennessee 37232, USA
    Clin Cancer Res 7:68-73. 2001
  8. ncbi request reprint Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer
    R F Devore
    Vanderbilt University, Nashville, TN 37232, USA
    J Clin Oncol 17:2710-20. 1999
  9. ncbi request reprint Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel
    Ildiko Csiki
    Department of Cancer Biology, Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA
    Clin Cancer Res 11:6634-40. 2005
  10. doi request reprint A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer
    Robert Mutter
    Vanderbilt University Medical Center, Nashville, Tennessee and University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Clin Cancer Res 15:2158-65. 2009

Collaborators

Detail Information

Publications87

  1. ncbi request reprint Targeted therapies in combination with chemotherapy in non-small cell lung cancer
    David H Johnson
    Vanderbilt Ingram Cancer Center and Division of Hematology and Oncology, Vanderbilt University School of Medicine Nashville, Tennessee 37232 6307, USA
    Clin Cancer Res 12:4451s-4457s. 2006
    ..However, in the absence of such biomarkers, clinical judgment, common sense, and innovative clinical trial design are necessary to avoid undue delay in drug development...
  2. ncbi request reprint Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
    David H Johnson
    Division of Hematology and Oncology, Vanderbilt University Medical School, 777 Preston Research Bldg, Nashville, TN, USA
    J Clin Oncol 22:2184-91. 2004
    ..To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer...
  3. ncbi request reprint Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: a historical perspective and the eastern cooperative oncology group experience
    D H Johnson
    Division of Medical Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA
    Chest 117:133S-137S. 2000
    ..Importantly, existing data indicate that chemotherapy is also cost-effective. Given these observations, it is appropriate today for patients with advanced NSCLC to receive chemotherapy...
  4. ncbi request reprint Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer
    B P Nicholson
    Vanderbilt University Cancer Center, Vanderbilt Cancer Center Affiliate Network, Nashville, TN, USA
    Clin Breast Cancer 1:136-43; discussion 144. 2000
    ..46 vs. 2.9 micrograms/mL; P = 0.02). Paclitaxel/5-fluorouracil/leucovorin is an active, well-tolerated regimen for patients with metastatic breast cancer...
  5. ncbi request reprint Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial
    H Choy
    Vanderbilt University Medical School, Nashville, TN, USA
    Lung Cancer 34:441-9. 2001
    ....
  6. ncbi request reprint Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial
    D H Johnson
    Department of Medicine, Vanderbilt University Medical School, Nashville, TN, USA
    J Clin Oncol 14:2054-60. 1996
    ..Based on these findings, a phase II trial of these agents in combination was conducted in patients with advanced NSCLC...
  7. ncbi request reprint Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study
    M H Jagasia
    Vanderbilt University, Nashville, Tennessee 37232, USA
    Clin Cancer Res 7:68-73. 2001
    ..The regimen was well tolerated, and the planned dose intensity was well maintained. Further evaluation of this combination in NSCLC is warranted...
  8. ncbi request reprint Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer
    R F Devore
    Vanderbilt University, Nashville, TN 37232, USA
    J Clin Oncol 17:2710-20. 1999
    ..A secondary objective was to characterize the pharmacokinetics and pharmacodynamics of CPT-11 and its active metabolite, SN-38...
  9. ncbi request reprint Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel
    Ildiko Csiki
    Department of Cancer Biology, Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA
    Clin Cancer Res 11:6634-40. 2005
    ..However, in light of the apparent survival prolongation in the subset with a marked decline in urinary PGE-M levels, further investigation of strategies designed to decrease PGE(2) synthesis in NSCLC seems warranted...
  10. doi request reprint A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer
    Robert Mutter
    Vanderbilt University Medical Center, Nashville, Tennessee and University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Clin Cancer Res 15:2158-65. 2009
    ..Cyclooxygenase (COX)-2 up-regulation plays an important role in the pathogenesis of lung cancer. Selective COX-2 inhibitors have promoted chemosensitivity and radiosensitivity of tumor cells in preclinical trials...
  11. ncbi request reprint Management of small cell lung cancer: current state of the art
    D H Johnson
    Division of Medical Oncology, Vanderbilt University Medical School, Nashville, TN 37232 5536, USA
    Chest 116:525S-530S. 1999
    ..Finally, the routine use of prophylactic cranial irradiation remains controversial, and currently should be reserved for patients in complete remission...
  12. ncbi request reprint Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer
    Dong Wook Kim
    Department of Radiation Oncology, Vanderbilt Ingram Cancer Center, Nashville, TN, USA
    Int J Radiat Oncol Biol Phys 63:1029-36. 2005
    ..Therefore, we sought to determine the impact of the response rate on survival for patients who were treated with combined modality therapy for LANSCLC...
  13. ncbi request reprint Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer
    Dong Wook Kim
    Department of Radiation Oncology, Vanderbilt University Medical Center, TN, USA
    Lung Cancer 50:235-45. 2005
    ..We sought to determine mature data from this database of patients, as well as to perform analysis of a cohort of patients who have achieved long term survival (LTS) when treated with this regimen...
  14. ncbi request reprint Gefitinib (Iressa) trials in non-small cell lung cancer
    David H Johnson
    Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center, 777 Preston Research Building, 2220 Pierce Avenue, Nashville, TN 37232 6307, USA
    Lung Cancer 41:S23-8. 2003
    ..Further studies employing single agent gefitinib as well as regimens employing a different sequencing of chemotherapy and gefitinib are planned in recurrent and previously untreated lung cancer patients...
  15. pmc Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab
    Alan B Sandler
    Vanderbilt University, Nashville, TN, USA
    J Clin Oncol 27:1405-12. 2009
    ..Retrospective case-control and cohort analyses were conducted to identify associated radiographic and clinical risk factors for PH...
  16. ncbi request reprint Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer
    Laine J Murphey
    Division of Clinical Pharmacology, Department of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Anal Biochem 334:266-75. 2004
    ..In summary, quantification of PGE-M using LC/MS/MS provides a facile and accurate method to assess PGE2 formation in human physiological and pathophysiological processes...
  17. ncbi request reprint Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer
    Alan B Sandler
    Division of Hematology Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Clin Cancer Res 10:4258s-4262s. 2004
    ..These studies will help to establish the role of bevacizumab in NSCLC...
  18. ncbi request reprint Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990
    Heather A Wakelee
    Department of Medicine, Division of Medical Oncology, Stanford Cancer Center, Stanford University, Stanford, California 94305 5826, USA
    Cancer 106:2208-17. 2006
    ....
  19. ncbi request reprint Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism
    Li Yang
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Cancer Res 66:9665-72. 2006
    ..Selective antagonism of the EP4 receptor may thus represent a novel therapeutic approach for the treatment of cancer and especially its propensity to metastasize...
  20. ncbi request reprint Novel therapies for the treatment of non-small cell lung cancer
    David H Johnson
    Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    Cancer Chemother Biol Response Modif 20:763-86. 2002
    ..In addition, we need new techniques to assist those who are already addicted to escape from tobacco's death grip. Sadly, most users of tobacco still fail to recognize the dangers of their habit. This needs to change!..
  21. ncbi request reprint Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    Alan Sandler
    Vanderbilt University, Nashville, TN, USA
    N Engl J Med 355:2542-50. 2006
    ..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers...
  22. doi request reprint Evarts A. Graham and the first pneumonectomy for lung cancer
    Leora Horn
    Division of Hematology and Oncology, Vanderbilt University School of Medicine, Vanderbilt Ingram Cancer Center, Nashville, TN 37232 6307, USA
    J Clin Oncol 26:3268-75. 2008
  23. ncbi request reprint Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer
    Li Yang
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Cancer Res 67:5587-93. 2007
    ..This effect is reversible in a subset of NSCLC upon treatment with an EGFR TKI...
  24. ncbi request reprint Targeted therapy in non-small cell lung cancer: myth or reality
    David H Johnson
    Division of Hematology and Oncology, Vanderbilt Ingram Comprehensive Cancer Center, 777 Preston Research Building, 2220 Pierce Avenue, Nashville, TN 37232 6307, USA
    Lung Cancer 41:S3-8. 2003
    ..If true, clinicians might then possess the ability to predict a tumor's clinical behavior and shape its density through specific, targeted interventions...
  25. ncbi request reprint Improving the evaluation of new cancer treatments: challenges and opportunities
    Mace L Rothenberg
    Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, Tennessee 37232 6307, USA
    Nat Rev Cancer 3:303-9. 2003
    ..How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?..
  26. ncbi request reprint Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer
    Pinar B Yildiz
    Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA
    J Thorac Oncol 2:893-901. 2007
    ..We hypothesized that matrix-assisted laser desorption ionization mass spectrometry (MALDI MS) analysis of the most abundant peptides in the serum may distinguish lung cancer cases from matched controls...
  27. ncbi request reprint A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer
    F A Greco
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
    Cancer Treat Rev 18:47-55. 1991
    ..045). Treatment-related toxicity was similar for the two regimens. These findings suggest that the addition of HMM to CAP chemotherapy prolongs the median survival for patients with limited residual disease advanced ovarian cancer...
  28. ncbi request reprint A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy
    J E Dowell
    Vanderbilt-Ingram Cancer Center, The Vanderbilt Clinic, Nashville, TN 37232-5536, USA
    Invest New Drugs 19:85-8. 2001
    ..Thirty-three percent of patients experienced > or = grade 2 fatigue. CONCLUSIONS: MGI-114, at this dose and schedule, does not have significant activity as second line therapy for patients with advanced NSCLC...
  29. ncbi request reprint Gemcitabine for the treatment of non-small-cell lung cancer
    D H Johnson
    Division of Hematology and Oncology, Vanderbilt University Medical School, Nashville, Tennessee, USA
    Oncology (Williston Park) 15:33-9. 2001
    ....
  30. ncbi request reprint Tyrosine kinase inhibitors-ZD1839 (Iressa)
    C L Arteaga
    Breast Cancer Program Vanderbilt-Ingram Cancer, Vanderbilt University School of Medicine, 777 Preston Research Building, Nashville, Tennessee 37232-6307, USA
    Curr Opin Oncol 13:491-8. 2001
    ..The early results of clinical trials indicate this drug possesses antitumor activity in certain malignancies of the upper aerodigestive tract...
  31. ncbi request reprint Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer
    Ildiko Csiki
    Department of Cancer Biology, Vanderbilt Ingram Cancer Center, Nashville, Tennessee 37232 6838, USA
    Cancer Res 66:143-50. 2006
    ..We also show that thioredoxin-1 stabilizes HIF-1alpha to induce hypoxia-responsive genes under normoxic conditions. Our results identify two new mechanisms for regulation of COX-2 expression in NSCLC...
  32. doi request reprint Anti-vascular endothelial growth factor treatment in combination with chemotherapy delays hematopoietic recovery due to decreased proliferation of bone marrow hematopoietic progenitor cells
    Sergey V Novitskiy
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University, 220 Pierce Avenue, Nashville, TN 37232, USA
    J Thorac Oncol 5:1410-5. 2010
    ..The purpose of the study was to elucidate the molecular mechanisms responsible for the development of neutropenia during the combination treatment...
  33. pmc A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group
    Leora Horn
    Department of Hematology Oncology, Vanderbilt University, Nashville, Tennessee, USA
    J Thorac Oncol 4:527-33. 2009
    ....
  34. ncbi request reprint Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models
    Jeffrey M Albert
    Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Clin Cancer Res 13:3033-42. 2007
    ..Ionizing radiation induces DNA strand breaks, suggesting that PARP-1 inhibition may sensitize tumor cells to radiation...
  35. ncbi request reprint Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer
    Carolyn Cao
    Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 5671, USA
    Cancer Res 66:11409-15. 2006
    ..Clinical trials are needed to determine the potential of this combination therapy in patients with locally advanced lung cancer...
  36. ncbi request reprint Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial
    K L Tedesco
    Vanderbilt Clinic, Vanderbilt University Medical Center, Nashville, TN, USA
    J Clin Oncol 22:1071-7. 2004
    ....
  37. ncbi request reprint Treatment of metastatic non-small-cell lung cancer
    D H Johnson
    Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical School, Nashville, Tennessee, USA
    Chest Surg Clin N Am 11:133-64. 2001
    ..In addition, clinicians need new techniques to assist those who are already addicted to escape from tobacco's death grip. Sadly, most users of tobacco still fail to recognize the dangers of their habit. This needs to change...
  38. ncbi request reprint Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer
    Jeffrey M Albert
    Department of Radiation Oncology, Vanderbilt University, 1301 Medical Center Drive, B 902 The Vanderbilt Clinic, Nashville, TN 37232 5671, USA
    Cancer Epidemiol Biomarkers Prev 16:1845-51. 2007
    ..Previous studies have examined the prognostic value of clusterin expression in various malignancies. In the present study, we examined clusterin staining in tumors resected from patients with non-small cell lung cancer (NSCLC)...
  39. pmc Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy
    Luigi Moretti
    Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Oncologist 14:1106-15. 2009
    ..Here, we investigated the association between different clinicopathological features and postoperative therapy and local control and survival in patients with resected pN2 NSCLC...
  40. ncbi request reprint Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma
    Eric T Shinohara
    Department of Radiation Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Cancer 103:1685-92. 2005
    ..In this study, the authors investigated whether nuclear or cytoplasmic staining of survivin was a prognostic marker for patients with lung carcinoma...
  41. ncbi request reprint Role of chemotherapy for palliation in the lung cancer patient
    Shannon Stinnett
    Division of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Support Oncol 5:19-24. 2007
    ..The efficacy of chemotherapy for the relief of symptoms and improvement in quality of life makes these drugs a fundamental part of palliative care...
  42. ncbi request reprint Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer
    A Bapsi Chakravarthy
    Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Clin Cancer Res 12:1570-6. 2006
    ....
  43. pmc Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597
    Vicki Keedy
    Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232, USA
    J Clin Oncol 26:4166-71. 2008
    ..This pilot phase I trial evaluated the safety and maximum-tolerated dose of p53 gene transfer using an adenovirus vector (Ad-p53) delivered via bronchoalveolar lavage (BAL) to patients with bronchioloalveolar lung carcinoma (BAC)...
  44. pmc Targeting the eicosanoid pathway in non-small-cell lung cancer
    Leora Horn
    Vanderbilt University School of Medicine, Vanderbilt Ingram Cancer Center, Division of Hematology and Medical Oncology, 2220 Pierce Avenue, Nashville, TN 37232, USA
    Expert Opin Ther Targets 13:675-88. 2009
    ..Consequently, inhibitors of COX-2 are being studied for their chemopreventative and therapeutic effects in individuals at high risk for lung cancer and patients with established cancers...
  45. ncbi request reprint ASCO in the 21st century: challenges and opportunities--ASCO presidential address 2005
    David H Johnson
    Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center, Nashville, TN, USA
    J Clin Oncol 24:1967-71. 2006
  46. pmc Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10
    Andrea Bezjak
    National Cancer Institute of Canada Clinical Trials Group, Cancer Centre of Southeastern Ontario, Kingston, ON, Canada
    J Clin Oncol 26:5052-9. 2008
    ..We report the QOL results of JBR.10, a North American, intergroup, randomized trial of adjuvant cisplatin and vinorelbine compared with observation in patients who have completely resected, stages IB to II NSCLC...
  47. ncbi request reprint The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer
    Leora Horn
    Division of Hematology and Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Thorac Oncol 2:377-83. 2007
    ..The treatment algorithm is based on currently available tumor- and host-related factors that affect prognosis...
  48. doi request reprint The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib
    Mary J Fidler
    Rush University Medical Center, Chicago, Illinois 60612, USA
    Clin Cancer Res 14:2088-94. 2008
    ..With these observations, we designed a phase II trial to evaluate the efficacy and safety of erlotinib plus celecoxib in advanced NSCLC...
  49. ncbi request reprint Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer
    Vincent A Miller
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 21:2094-100. 2003
    ..This pilot trial combined gefitinib with carboplatin and paclitaxel to define the toxicities of the combination and assess drug-drug interactions in untreated advanced NSCLC patients...
  50. ncbi request reprint Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
    David H Johnson
    J Clin Oncol 21:2227-9. 2003
  51. ncbi request reprint Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    Joan H Schiller
    University of Wisconsin Hospital and Clinics, Madison, USA
    N Engl J Med 346:92-8. 2002
    ..We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non-small-cell lung cancer...
  52. ncbi request reprint Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592
    David T Eton
    Evanston Northwestern Healthcare and Northwestern University, Evanston, IL 60201, USA
    J Clin Oncol 21:1536-43. 2003
    ..To determine the ability of longitudinal patient-reported health (PRH) scores to enhance prediction of clinical outcomes beyond baseline scores...
  53. ncbi request reprint A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)
    Kishan J Pandya
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    J Thorac Oncol 2:1036-41. 2007
    ..To study the progression-free survival (PFS) and toxicity with 25- or 250-mg doses of temsirolimus (CCI-779) after induction chemotherapy in patients with extensive small-cell lung cancer...
  54. doi request reprint Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA
    J Clin Oncol 26:60-5. 2008
    ..We conducted a subset analysis of ECOG 4599 to determine the outcome for elderly patients...
  55. doi request reprint Novel strategies for the treatment of lung cancer: modulation of eicosanoids
    Michael G Backlund
    J Clin Oncol 26:825-7. 2008
  56. ncbi request reprint Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study
    Afshin Dowlati
    University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio 44016, USA
    Clin Cancer Res 14:1407-12. 2008
    ....
  57. doi request reprint Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib
    Vincent A Miller
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard Building, Room 1012, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:1472-8. 2008
    ..We conducted this phase II trial to determine the efficacy of erlotinib in patients with bronchioloalveolar carcinoma (BAC) and adenocarcinoma, BAC subtype, and to determine molecular characteristics associated with response...
  58. ncbi request reprint Does gefitinib shorten lung cancer survival? Chaos redux
    Vicki L Keedy
    J Clin Oncol 26:2428-30. 2008
  59. ncbi request reprint Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial
    Corey J Langer
    C J Langer, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Natl Cancer Inst 94:173-81. 2002
    ....
  60. ncbi request reprint TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
    Roy S Herbst
    University of Texas M D Anderson Cancer Center, Houston, USA
    J Clin Oncol 23:5892-9. 2005
    ..Erlotinib was combined with chemotherapy to determine if it could improve the outcome of patients with NSCLC...
  61. pmc Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer
    Lawrence H Einhorn
    Indiana Cancer Pavilion, Indianapolis, Indiana, USA
    J Thorac Oncol 3:545-55. 2008
  62. ncbi request reprint Seminars in oncology. Introduction
    Paul A Bunn
    Department of Medicine, University of Colorado Cancer Center, Denver, CO 80262, USA
    Semin Oncol 29:1-2. 2002
  63. ncbi request reprint Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10
    Carmela Pepe
    Division of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    J Clin Oncol 25:1553-61. 2007
    ..This retrospective study evaluated the influence of age on survival, adjuvant chemotherapy delivery, and toxicity in National Cancer Institute of Canada (NCIC) Clinical Trials Group study JBR.10...
  64. ncbi request reprint Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594
    Heather A Wakelee
    Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305 5826, USA
    J Thorac Oncol 1:441-6. 2006
    ..E1594 randomized patients with advanced NSCLC to one of four platinum doublets and found that all four regimens had comparable efficacy...
  65. ncbi request reprint EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer
    Sarita Dubey
    University of California, San Francisco, San Francisco, California 94115, USA
    J Thorac Oncol 1:406-12. 2006
    ..The authors hypothesized that a shorter length of tumor SSR would be associated with poorer survival in patients with non-small cell lung cancer (NSCLC)...
  66. ncbi request reprint Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data
    Tien Hoang
    University of Wisconsin Medical School, 600 Highland Ave, K4 562, Madison, WI, USA
    J Clin Oncol 23:175-83. 2005
    ....
  67. ncbi request reprint Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    J Clin Oncol 22:785-94. 2004
    ..This phase III, randomized, placebo-controlled, double-blind trial evaluated gefitinib plus paclitaxel and carboplatin in chemotherapy-naive patients with advanced NSCLC...
  68. ncbi request reprint Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials
    Daphne W Bell
    Massachusetts General Hospital Cancer Center and Department of Pathology, Harvard Medical School, Charlestown, MA 02129, USA
    J Clin Oncol 23:8081-92. 2005
    ..The goal of this study was to determine the contribution of molecular alterations in EGFR to response and survival within the phase II (IDEAL) and phase III (INTACT) trials of gefitinib...
  69. ncbi request reprint Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease
    Steven M Keller
    Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY 10467, USA
    J Thorac Cardiovasc Surg 128:130-7. 2004
    ....
  70. ncbi request reprint Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
    David A Eberhard
    Department of Pathology, Genentech Inc, San Francisco, CA, USA
    J Clin Oncol 23:5900-9. 2005
    ..KRAS is frequently activated in NSCLC. The relationship of KRAS mutations to outcome after EGFR inhibitor treatment has not been described...
  71. ncbi request reprint Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma
    Douglas W Blayney
    Wilshire Oncology Medical Group, Inc, Pasadena, California, USA
    Oncologist 10:138-49. 2005
    ..We conclude that the delivery of myelosuppressive chemotherapy in both a dose-intense and a dose-dense manner is feasible with filgrastim support...
  72. ncbi request reprint Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group
    Heather A Wakelee
    Stanford Clinical Cancer Center, 875 Blake Wilbur Drive, Room 2231, Stanford, CA 94305 5826, USA
    Lung Cancer 48:389-97. 2005
    ..The risk of DID following resection of stages II and IIIA NSCLC is not increased in patients who received PORT or CPORT...
  73. ncbi request reprint Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities
    Vincent A Miller
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Room 1012 H Building, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 23:3288-93. 2005
    ....
  74. ncbi request reprint Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lu
    Chandra P Belani
    University of Pittsburgh Medical Center Cancer Pavilion, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    J Clin Oncol 23:3760-7. 2005
    ..To compare once-daily radiation therapy (qdRT) with hyperfractionated accelerated radiation therapy (HART) after two cycles of induction chemotherapy...
  75. ncbi request reprint Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1
    Giuseppe Giaccone
    Vrije Universiteit Medical Center, Department of Oncology, De Boelelaan 1117, 1081 Amsterdam, The Netherlands
    J Clin Oncol 22:777-84. 2004
    ..Gefitinib has demonstrated encouraging efficacy in advanced NSCLC in phase II trials in pretreated patients, and a phase I trial of gefitinib in combination with gemcitabine and cisplatin showed favorable tolerability...
  76. ncbi request reprint Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, Boston 02114, and University of Colorado Cancer Center, Aurora, USA
    Clin Cancer Res 12:4365s-4371s. 2006
  77. ncbi request reprint Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598
    Corey J Langer
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 22:1180-7. 2004
    ..The Eastern Cooperative Oncology Group therefore launched a phase II study evaluating combination carboplatin, paclitaxel, and trastuzumab in patients with advanced NSCLC...
  78. ncbi request reprint Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancer
    David H Johnson
    J Natl Cancer Inst 99:415-8. 2007
  79. ncbi request reprint Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599
    Corey Langer
    Thoracic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 25:418-23. 2007
    ..PS-2 patients on ECOG 1594 had a median survival (MS) of only 4.1 months and 1-year overall survival (OS) of 19%. Three percent had grade 5 toxicity...
  80. pmc Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590
    Daniel B Costa
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA, United States
    Lung Cancer 56:97-103. 2007
    ..This is the first comprehensive study of this transcription factor in patients with NSCLC...
  81. ncbi request reprint PDGFR-beta expression in small cell lung cancer patients
    Eric T Shinohara
    Department of Medicine, Abington Memorial Hospital, Abington, PA, USA
    Int J Radiat Oncol Biol Phys 67:431-7. 2007
    ..Data in non-small-cell cancer cell lines have suggested that PDGFR is a therapeutic target for drug development. In the current study PDGFR-beta expression and prognostic value in small cell lung cancer (SCLC) was investigated...
  82. ncbi request reprint Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)
    Valerie W Rusch
    Thoracic Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 25:313-8. 2007
    ..On the basis of improved outcomes in other subsets of stage III NSCLC, this trial tested the feasibility of induction chemoradiotherapy for SS NSCLC...
  83. ncbi request reprint An advance in small-cell lung cancer treatment--more or less
    Janessa Laskin
    J Natl Cancer Inst 95:1099-101. 2003
  84. ncbi request reprint Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer
    Steven M Keller
    Department of Cardiothoracic Surgery, The Montefiore Medical Center, 3400 Bainbridge Ave, Suite 5B, Bronx, NY 10467, USA
    Lung Cancer 42:79-86. 2003
    ..The majority of SPTs occur outside the aerodigestive tract. Following development of a non-skin SPT, the survival difference between patients who had received adjuvant CRT and those treated with adjuvant RT alone was not significant...
  85. ncbi request reprint Did targeted therapy fail cyclooxygenase too?
    Ildiko Csiki
    J Clin Oncol 24:4798-800. 2006
  86. ncbi request reprint American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003
    David G Pfister
    American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, 1900 Duke St, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 22:330-53. 2004
  87. ncbi request reprint Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung canc
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, Biostatistics and Diagnostic Radiology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 23:2544-55. 2005
    ..Preclinical data in various xenograft models produced greater growth inhibition than with either agent alone. Additionally, both agents have demonstrated benefit in patients with previously treated non-small-cell lung cancer (NSCLC)...